Letter: The feasibility and safety of accelerated infliximab infusions in patients with inflammatory bowel disease.
Gastroenterology Department, Complejo Hospitalario de Navarra, Pamplona, Spain. onantes@yahoo.es.
Ó
Ó
Nantes
C
C
Rodríguez
M
M
Basterra
M
M
Gómez
K
K
Cambra
B
B
Ibáñez
I
I
Fernandez-Urien
A
A
Arín
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D025242:Spondylarthropathies / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D005765:Gastrointestinal Agents